The global immunoglobulin market size accounted for USD 14.32 billion in 2024, grew to USD 15.35 billion in 2025, and is projected to surpass around USD 28.70 billion by 2034, representing a healthy CAGR of 7.2% between 2024 and 2034. The North America immunoglobulin market size is calculated at USD 6.59 billion in 2024 and is expected to grow at the fastest CAGR of 7.23%% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunoglobulin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunoglobulin Market, by Application, 2024-2034
8.1.1 Hypogammaglobulinemia
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Immunodeficiency Disease
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Myasthenia Gravis
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Multifocal Motor Neuropathy
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Idiopathic Thrombocytopenic Purpura
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Inflammatory Myopathies
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Specific Antibody Deficiency
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Guillain Barre Syndrome
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Others
8.1.10.1. Market Revenue and Forecast (2021-2034)
9.1. Immunoglobulin Market, by Product, 2024-2034
9.1.1. IgA
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. IgG
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. IgM
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. IgE
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. IgD
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Immunoglobulin Market, by Mode of Delivery, 2024-2034
10.1.1. Intravenous
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Subcutaneous
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Mode of Delivery (2021-2034)
12.1. Grifols, S.A.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Shire
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CSL Behring
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Kedrion S.p.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Octapharma
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Baxter International Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biotest AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bio Products Laboratory Ltd. (BPL)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. China Biologic Products Holdings, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. LFB SA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample